Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double‐blind, placebo‐controlled phase 3 trial

Cadot, Pierre; Hensel, Patrick; Bensignor, Emmanuel; Hadjaje, Céline; Marignac, Geneviève; Beco, Luc; Fontaine, Jacques; Jamet, Jean-François; Georgescu, Gabriela; Campbell, Karen; Cannon, Andréa; C. Osborn, Sarah; Messinger, Linda; Gogny‐Goubert, Michel; Dubreuil, Patrice; Moussy, Alain; Hermine, Olivier

doi:10.1111/j.1365-3164.2011.00990.x

Public

Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double‐blind, placebo‐controlled phase 3 trial

Published in Veterinary Dermatology • Jun 13, 2011

Authors:

Pierre Cadot

Patrick Hensel

Emmanuel Bensignor

Abstract

This study investigated the efficacy and safety of masitinib, a selective tyrosine kinase inhibitor capable of downregulating mast cell functions, for treatment of canine atopic dermatitis (CAD). Dogs with confirmed CAD received masitinib at 12.5 mg/kg/day (n = 202) or control (n = 104) for 12 weeks...

Subject

Atopic dermatitis

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!